Please ensure Javascript is enabled for purposes of website accessibility

Pfizer, BioNTech Choose Coronavirus Vaccine Candidate to Advance to Phase 2/3 Trial

By Eric Volkman – Updated Jul 27, 2020 at 9:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The two companies have selected one of the four candidates they were developing and testing in early-stage trials.

Two companies considered to be advanced in their pursuit of a coronavirus vaccine, Pfizer (PFE -0.77%) and BioNTech (BNTX -0.28%), have selected one candidate for advancement to a phase 2/3 clinical study. The two companies, which are collaborating on the vaccine effort, said Monday in a joint press release that they have chosen BNT162b2, one of four candidates they were testing.

The selection was made after evaluating data from phase 1/2 clinical trials of all four candidates. Pfizer and BioNTech said they also consulted with the Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research and other regulators on the choice.

A medical professional using a microscope.

Image source: Getty Images.

The companies said that "[p]reliminary clinical phase 1/2 data from nearly 120 patients demonstrated a favorable overall tolerability profile for BNT162b2, as compared to BNT162b1, with generally mild to moderate and transient (1-2 days) systemic events, such as fever, fatigue, and chills, and no serious adverse events."

Pfizer and BioNTech added that they have finalized the phase 2/3 study protocol, again incorporating responses from healthcare regulators around the world. As many as 30,000 people will be enrolled in this clinical trial, and it will consist of a diverse population of adults aged 18 to 85. It will take place in 39 U.S. states and in countries such as Argentina and BioNTech's native Germany.

All of the Pfizer-BioNTech coronavirus vaccine candidates work by using messenger RNA (mRNA) to teach the body's cells how to make antibodies that can attack the COVID-19 virus.

The fortunes of the two companies were mixed in trading on Monday. Pfizer fell marginally by 0.3%, while BioNTech outpaced many peer biotech stocks and the top equities indexes by rising 2.8%.


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
$44.12 (-0.77%) $0.34
BioNTech SE Stock Quote
BioNTech SE
$137.19 (-0.28%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.